Search

Your search keyword '"V. S. Katikireddi"' showing total 4 results
Start Over "V. S. Katikireddi" Publication Year Range Last 10 years
4 results on '"V. S. Katikireddi"'

1. Society for Cardiovascular Magnetic Resonance 2019 Case of the Week series

Author

Arun Dahiya, Charles Chao, John Younger, Julia Kar, Bryant M. Baldwin, Michael V. Cohen, Shane Joseph, Anam Chowdhry, Maria S. Figarola, Christopher Malozzi, M. Farhan Nasser, Yassar Nabeel, Rajiv Shah, J. Michael Kennen, Ashish Aneja, Sameh Khalil, Sara Ragab, Omnia Mohammed, Taher Moustafa, Ahmed Hamdy, Shimaa Ahmed, Ahmed Heny, Maha Taher, Madhusudan Ganigara, Arushi Dhar, Nilanjana Misra, Jafar Alzubi, Kurian Pannikottu, Ahmad Jabri, Vinayak Hedge, Anmar Kanaa’n, Joseph Lahorra, Dominique de Waard, David Horne, Santokh Dhillon, Aoife Sweeney, Christian Hamilton-Craig, V. S. Katikireddi, Allan J. Wesley, Chris Hammet, Jason N. Johnson, and Sylvia S. M. Chen

Subjects
Cardiomyopathy, Cardiac tumor, MRI, Eosinophilic granulomatosis, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract The Society for Cardiovascular Magnetic Resonance (SCMR) is an international society focused on the research, education, and clinical application of cardiovascular magnetic resonance (CMR). The SCMR web site ( https://www.scmr.org ) hosts a case series designed to present case reports demonstrating the unique attributes of CMR in the diagnosis or management of cardiovascular disease. Each clinical presentation is followed by a brief discussion of the disease and unique role of CMR in disease diagnosis or management guidance. By nature, some of these are somewhat esoteric, but all are instructive. In this publication, we provide a digital archive of the 2019 Case of the Week series as a means of further enhancing the education of those interested in CMR and as a means of more readily identifying these cases using a PubMed or similar search engine.

Published
2021
Full Text
View/download PDF

2. Society for Cardiovascular Magnetic Resonance 2019 Case of the Week series

Author

Ahmed Heny, John F. Younger, Arushi Dhar, J. Michael Kennen, Vinayak Hedge, Omnia Mohammed, Anmar Kanaa'N, Bryant M. Baldwin, Shane Joseph, Maha Taher, Dominique de Waard, Santokh Dhillon, Madhusudan Ganigara, Yassar Nabeel, Jason N. Johnson, Jafar Alzubi, Christian Hamilton-Craig, Rajiv R. Shah, Ahmed Hamdy, Ahmad Jabri, Aoife Sweeney, Chris Hammet, Joseph A. Lahorra, Nilanjana Misra, Arun Dahiya, Sameh Khalil, Taher Moustafa, Sara Ragab, Ashish Aneja, Christopher Malozzi, Michael V. Cohen, Sylvia S. M. Chen, Maria S. Figarola, Charles Chao, Julia Kar, David Horne, Kurian Pannikottu, Shimaa Abdelrahman Ahmed, V. S. Katikireddi, Allan J. Wesley, Anam Chowdhry, and M. Farhan Nasser

Subjects
Cardiac tumor, medicine.medical_specialty, lcsh:Diseases of the circulatory (Cardiovascular) system, Cardiomyopathy, media_common.quotation_subject, Antineoplastic Agents, Review, Disease, Churg-Strauss Syndrome, 030204 cardiovascular system & hematology, Ventricular Function, Left, 030218 nuclear medicine & medical imaging, Diagnosis, Differential, Heart Neoplasms, Ventricular Dysfunction, Left, Young Adult, 03 medical and health sciences, Presentation, 0302 clinical medicine, Predictive Value of Tests, Humans, Medicine, Radiology, Nuclear Medicine and imaging, Medical physics, Cardiac Tumors, Web site, Angiology, media_common, Radiological and Ultrasound Technology, medicine.diagnostic_test, business.industry, Thrombosis, Magnetic resonance imaging, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Cardiotoxicity, lcsh:RC666-701, Female, Cardiology and Cardiovascular Medicine, business, MRI, Eosinophilic granulomatosis
Abstract

The Society for Cardiovascular Magnetic Resonance (SCMR) is an international society focused on the research, education, and clinical application of cardiovascular magnetic resonance (CMR). The SCMR web site (https://www.scmr.org) hosts a case series designed to present case reports demonstrating the unique attributes of CMR in the diagnosis or management of cardiovascular disease. Each clinical presentation is followed by a brief discussion of the disease and unique role of CMR in disease diagnosis or management guidance. By nature, some of these are somewhat esoteric, but all are instructive. In this publication, we provide a digital archive of the 2019 Case of the Week series as a means of further enhancing the education of those interested in CMR and as a means of more readily identifying these cases using a PubMed or similar search engine.

Published
2021

3. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis

Author

L, Cummins, V S, Katikireddi, S, Shankaranarayana, K Y C, Su, E, Duggan, V, Videm, H, Pahau, and R, Thomas

Subjects
Adult, Male, Dose-Response Relationship, Drug, Anti-Inflammatory Agents, Non-Steroidal, Remission Induction, Isoxazoles, Middle Aged, United States, Arthritis, Rheumatoid, Sulfasalazine, Methotrexate, Treatment Outcome, Antirheumatic Agents, Humans, Drug Therapy, Combination, Female, Prospective Studies, Immunosuppressive Agents, Leflunomide, Aged, Follow-Up Studies, Hydroxychloroquine
Abstract

While efficacy of combination treatment with methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) ('triple therapy') has been shown in clinical trials, few studies have examined its longevity in a real-life setting.Our aim was to assess the tolerability, longevity and efficacy of a triple disease-modifying anti-rheumatic drug (DMARD) regimen initiated in new-onset rheumatoid arthritis (RA) patients.Patients who met 1987 American College of Rheumatology criteria for RA with disease duration less than 2 years were offered triple therapy upon diagnosis. Treatment was intensified according to a response-driven step-up algorithm, which included progression to leflunomide (LEF) or a biologic agent.Of 181 new-onset RA patients, 119 commenced triple therapy. Median duration of triple therapy was 39 weeks, and 23.5% remained on it at last follow up, with median follow up 104 weeks. Continuous therapy with any three-DMARD combination (including LEF) occurred in 32% at last follow up, with median duration of 70 weeks. Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients. SSZ accounted for 49% of initial drug withdrawals for an adverse event. Continuation of three-drug therapy did not significantly influence the proportion of patients achieving remission or low disease activity (LDA).Triple therapy in new-onset RA was reasonably well tolerated, persisting for median 39 weeks. SSZ intolerance commonly reduces longevity of triple therapy. Treating to the target of remission or LDA is more important than the number of DMARD continued.

Published
2015

4. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.

Author

Cummins, L., Katikireddi, V. S., Shankaranarayana, S., Su, K. Y. C., Duggan, E., Videm, V., Pahau, H., and Thomas, R.

Subjects
ANTIRHEUMATIC agents, COMBINATION drug therapy, CHI-squared test, CHLOROQUINE, METHOTREXATE, QUESTIONNAIRES, REGRESSION analysis, RHEUMATOID arthritis, STATISTICS, SULFONAMIDES, SURVIVAL analysis (Biometry), T-test (Statistics), PROPORTIONAL hazards models, DATA analysis software, DESCRIPTIVE statistics, MANN Whitney U Test
Abstract

Background While efficacy of combination treatment with methotrexate (MTX), sulfasalazine (SSZ) and hydroxychloroquine (HCQ) ('triple therapy') has been shown in clinical trials, few studies have examined its longevity in a real-life setting. Aim Our aim was to assess the tolerability, longevity and efficacy of a triple disease-modifying anti-rheumatic drug (DMARD) regimen initiated in new-onset rheumatoid arthritis (RA) patients. Methods Patients who met 1987 American College of Rheumatology criteria for RA with disease duration less than 2 years were offered triple therapy upon diagnosis. Treatment was intensified according to a response-driven step-up algorithm, which included progression to leflunomide (LEF) or a biologic agent. Results Of 181 new-onset RA patients, 119 commenced triple therapy. Median duration of triple therapy was 39 weeks, and 23.5% remained on it at last follow up, with median follow up 104 weeks. Continuous therapy with any three-DMARD combination (including LEF) occurred in 32% at last follow up, with median duration of 70 weeks. Cessation of at least one of MTX, SSZ or HCQ occurred because of an adverse event in 38%, remission in 7% and incomplete response in 28% of patients. SSZ accounted for 49% of initial drug withdrawals for an adverse event. Continuation of three-drug therapy did not significantly influence the proportion of patients achieving remission or low disease activity (LDA). Conclusions Triple therapy in new-onset RA was reasonably well tolerated, persisting for median 39 weeks. SSZ intolerance commonly reduces longevity of triple therapy. Treating to the target of remission or LDA is more important than the number of DMARD continued. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results